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Abstract
We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-
containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was
negative for HER-2 as determined by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (1+,
and ratio, 1.1), but examination of the recurrent lymph node metastasis showed positivity for HER-2 by FISH (ratio,
5.2). No lesions were detected in either her left breast or in other organs, and the patient was diagnosed as having
HER-2-positive recurrent disease. Combination chemotherapy using weekly paclitaxel and trastuzumab was
initiated, and a clinically complete response was achieved. This report suggests the benefit of routine evaluation of
HER-2 status in recurrent breast cancer with the introduction of HER-2-targeting agents.
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Background
Recently, several reports have demonstrated that there
are substantial discordances in hormone receptor
expression and HER-2 status between primary tumors
and metastases, which could alter the treatment and
prognosis of recurrent breast cancer [1-5]. The discor-
dance between HER-2 status in primary tumors and in
metastatic sites occurs less frequently than the discor-
dance between hormonal receptors [2-4,6], and the
impact on prognosis is still unknown [7]. We here
report on a case of recurrent HER-2-positive breast can-
cer showing a clinically complete response to trastuzu-
mab-containing chemotherapy 6 years after primary
treatment of triple-negative breast cancer.
Case presentation
A 49-year-old premenopausal woman had undergone
total mastectomy and sentinel lymph node biopsy for
stage I right breast cancer in April 2003. The histologi-
cal diagnosis was invasive ductal carcinoma of the right
breast with no metastasis in one sentinel lymph node.
Immunohistochemical (IHC) examinations of the tumor
cells showed negative results for both estrogen receptor
(ER) and progesterone receptor (PgR) and showed weak
membrane staining of HER-2 (1+ score) (Figure 1).
Fluorescence in situ hybridization (FISH) analysis found
no HER-2 amplification in the primary tumor (ratio,
1.1) (Figure 2). The patient received postoperative adju-
vant chemotherapy consisting of 4 cycles of epirubicine
75 mg/m
2 and cyclophosphamide 600 mg/m
2 every 3
weeks. After the completion of adjuvant chemotherapy,
she became postmenopausal and was followed without
any treatment.
Six years and 10 months after primary surgery, she
noticed lumps in her left axilla. An ultrasonography and
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and infraclavicular lymph node swellings. FDG-PET (2-
[18F]Fluoro-2-deoxyglucose positron emission tomogra-
phy) showed an accumulation of FDG in the left axilla
and infraclavicular lymph nodes (Figure 3). The patient
subsequently underwent ultrasonography-guided fine
needle aspiration (FNA) cytology of the left axilla lymph
node (Figure 4). Cytological findings revealed breast
cancer metastases and FISH analysis of FNA samples
showed HER-2 gene amplification (ratio 5.7) (Figure 5).
Immunohistochemical examinations of FNA sample
showed positive results for both ER and PgR. A PET-CT
scan did not reveal any other metastases, and no malig-
nancies were detected in any other organs, including her
left breast. With these clinical and cytological findings,
she was diagnosed as having HER-2-positive recurrent
breast cancer after primary treatment of right triple-
negative breast cancer. At this point, there was the pos-
sibility of left axillary lymph node metastases from right
breast cancer or left occult breast cancer. Initially, we
decided to perform chemotherapy before surgery to
evaluate the responsiveness to chemotherapy.
She was treated with weekly paclitaxel (80 mg/m
2,3
weeks on, 1 week off) in combination with weekly tras-
tuzumab (initially 4 mg/kg followed by 2 mg/kg every
week). After 3 courses of administrations, a PET-CT
scan showed complete remission of swelling lymph
nodes and no accumulation of FDG was detected (Fig-
ure 6). The elevated CEA was normalized. Complete
remission of disease was maintained for more than 4
weeks with normalized tumor markers and she was
Figure 1 Immunohistochemical staining for HER-2 protein
overexpression using the HercepTest showed weak membrane
staining in 30% of the primary tumor, corresponding to a 1+
score.
Figure 2 Fluorescence in situ hybridization analysis of the
primary tumor showed a lack of HER-2 amplification, with a
ratio of 1.1.
Figure 3 FDG-PET showed swelling of the left axilla and
infraclavicular lymph nodes with FDG accumulation (SUV max
4.5). No accumulation was observed in other organs, including the
left breast.
Figure 4 Fine needle aspiration cytology demonstrated sheet
clusters of atypical epithelial cells that showed high a nuclear
cytoplasmic ratio, and the appearance of a nucleolus suggests
recurrent breast cancer (Papanicolau).
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RECIST criteria. No severe adverse event above grade 3
was noted (alopecia grade 1, neutropenia grade 2). She
underwent the combination chemotherapy of weekly
paclitaxel and trastuzumab for 1 year and continues to
showe a complete remission ofd i s e a s ew i t ht o l e r a b l e
neuropathy. Monotherapy with trastuzumab alone che-
motherapy is ongoing and additional radiotherapy and
surgery are being considered to confirm the local
control.
Discussion
With the introduction of molecular targeting therapies,
such as those utilizing monoclonal antibodies or small-
molecule tyrosine kinase inhibitors directed to HER2
signaling and hormonal agents, hormone receptor
expression and HER-2 status have become the most
important prognostic and predictive factors in breast
cancer [8-10]. It is currently recommended that these
biomarkers be routinely evaluated in every case of pri-
mary invasive breast cancer [1,5]. Meanwhile, confirma-
tory biopsy and reevaluation of biomarkers are not
mandatory, and biopsy of metastatic lesions is rarely
performed, especially for distant metastases. Thus, the
decision to carry out systemic treatment for recurrent
and metastatic breast cancer is based on the ER, PgR,
and HER-2 status of the primary tumor. However, a
substantial proportion of patients with metastatic breast
cancer have been reported to have discordances in the
expression of these biomarkers between primary and
metastatic disease in previous studies. Recent retrospec-
tive reviews have shown discordance between the pri-
mary tumor and metastases in 14%-48% for ER and PgR
status, and in 2%-13% for HER-2 status. A prospective
study also demonstrated changes in hormone receptor
status in 40% and in HER-2 status in 8% of patients
with metastatic breast cancer [1-3,5]. Most importantly,
patients with discordant expression of these receptors
have been reported to show a decreased rate of post-
recurrence survival due to inappropriate use of targeted
therapies [2,4]. Considering the therapeutic impact of
targeted therapies in breast cancer, misunderstanding in
the receptor profile of metastatic lesions can lead to
suboptimal therapy and decreased survival.
Compared with hormone receptor status, discordance
in the HER-2 status between primary and metastatic
lesions is less common, and the impact of this discor-
dance on the prognosis of recurrent breast cancer is less
clear [6,7]. However, with the introduction of trastuzu-
mab, the HER-2 status of metastatic disease has become
one of the most important predictive and prognostic
factors in patients with recurrent breast cancer. Clinical
trials have shown a significant survival benefit from tras-
tuzumab in addition to the chemotherapy agent in HER-
2-positive advanced breast cancer [11,12]. An institu-
tional-based review also showed that women with HER-
2-positive disease who received trastuzumab had an
improved prognosis compared with women who did not
receive such treatment [13]. However, it is less clear
whether the reevaluation of HER -2 status in metastatic
lesions has an impact on the prognosis of patients with
recurrent breast cancer. In this case report, the patient
was initially diagnosed with triple-negative breast cancer,
but a reevaluation of the metastatic disease showed her
to be HER-2-positive by FISH, and she was diagnosed
with HER-2-positive metastatic breast cancer. Based on
these findings, she was administered combination che-
motherapy using weekly paclitaxel and trastuzumab, and
clinically complete remission was immediately achieved
and maintained for over 1 year. She is currently disease-
free, and an excellent prognosis is expected. The inci-
dence of a discordance in HER-2 status between
Figure 5 Fluorescence in situ hybridization (FISH) analysis of
the lymph node metastasis showed strong HER-2 amplification
in most cells, with a FISH ratio of 5.6.
Figure 6 After administration of three cycles of combination
chemotherapy using weekly paclitaxel and trastuzumab, the
lymph node swelling disappeared and there was no apparent
accumulation of FDG.
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an altered HER-2 status could have substantial clinical
impact in patients with recurrent breast cancer with the
introduction of HER-2-targeting agents. With these
findings, sampling and assessment of the metastatic
lesion should be considered in patients with recurrent
disease without excessive involvement.
There are some limitations to this case report. First,
one cannot completely deny the possibility of left occult
breast cancer with axillary lymph node metastases.
Although the frequency of occult breast cancer is
reportedly small, accounting for less than 1% of all
breast cancers [14], and no lesion was detected in her
left breast by detailed examination at the diagnosis of
recurrent breast cancer, there remains a small possibility
of occult HER-2-positive left breast cancer with regional
lymph node metastases. Second, in this case, HER-2
gene amplification of recurrent disease was detected in
samples of fine needle aspirates by HER-2 FISH. In a
daily setting, HER-2 FISH is performed on tissue sec-
tions according to published guidelines [15]. There
could be a discrepancy in HER2 gene amplification
between tissue and cytological samples. However, it has
previously been reported that HER2 amplification in
FNA samples shows a good correlation with the findings
of FISH and IHC results from corresponding histological
sections [16]. In our institute, we have also confirmed
the concordance between tissues and cytology samples
in HER-2 FISH results. Thus, the HER-2 FISH results
from FNA samples in this case correctly revealed the
HER-2 status of metastatic disease.
Conclusion
We observed a case of HER-2-positive recurrent breast
cancer showing a clinically complete response to trastu-
zumab-containing chemotherapy after primary treat-
ment of triple-negative breast cancer. Reassessment of
the HER-2 status of metastatic lesions should be consid-
ered in all patients without excessive involvement.
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